Suppr超能文献

在晚期乳腺癌女性中,先用氨鲁米特抑制芳香化酶后,再用4-羟基雄烯二酮抑制芳香化酶。

Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer.

作者信息

Murray R, Pitt P

机构信息

Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia.

出版信息

Breast Cancer Res Treat. 1995 Sep;35(3):249-53. doi: 10.1007/BF00665976.

Abstract

One hundred and twelve post menopausal or post oophorectomy women with advanced breast cancer (BC) who had all previously had aminoglutethimide (AG) were treated with the potent aromatase inhibitor 4-hydroxy androstenedione (4-OHA). Twenty three women (21%) had a partial response to 4-OHA while another twenty five patients (22%) had stabilization of previously progressing disease. Patients responded to 4-OHA both after previously responding to then relapsing on, and after failing to respond to aminoglutethimide. Toxicity was minimal. This study shows that potent aromatase inhibition with 4-OHA is effective in women with advanced BC who have already been treated with a less potent aromatase inhibitor, and suggests that relative changes in oestrogen levels may be more important than absolute levels.

摘要

112名绝经后或卵巢切除术后的晚期乳腺癌(BC)女性患者,她们之前均接受过氨鲁米特(AG)治疗,随后接受强效芳香化酶抑制剂4-羟基雄烯二酮(4-OHA)治疗。23名女性(21%)对4-OHA有部分反应,另有25名患者(22%)之前进展的疾病病情稳定。患者在之前对AG有反应后复发,以及对氨鲁米特无反应后,对4-OHA均有反应。毒性极小。本研究表明,用4-OHA进行强效芳香化酶抑制对已接受过较弱效芳香化酶抑制剂治疗的晚期BC女性有效,并提示雌激素水平的相对变化可能比绝对水平更重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验